Study on Genetic Variants Linked to Alzheimer's Disease
Author Information
Author(s): Minerva M Carrasquillo, Olivia Belbin, Talisha A Hunter, Li Ma, Gina D Bisceglio, Fanggeng Zou, Julia E Crook, V Shane Pankratz, Sigrid B Sando, Jan O Aasly, Maria Barcikowska, Zbigniew K Wszolek, Dennis W Dickson, Neill R Graff-Radford, Ronald C Petersen, Peter Passmore, Kevin Morgan, Steven G Younkin
Primary Institution: Mayo Clinic College of Medicine
Hypothesis
Are the genetic variants EPHA1 and CD33 associated with late-onset Alzheimer's disease?
Conclusion
The study confirms that variants in EPHA1 and CD33 are associated with an increased risk of late-onset Alzheimer's disease.
Supporting Evidence
- EPHA1 and CD33 variants were replicated in a large independent dataset.
- The study included 2,634 Alzheimer's patients and 4,201 controls.
- Odds ratios for EPHA1 and CD33 were comparable to previous studies.
- Significant associations were found for EPHA1 (p = 5 × 10-4) and CD33 (p = 0.049).
- Meta-analysis showed no significant series heterogeneity.
Takeaway
Scientists looked at genes to see if they are linked to Alzheimer's disease and found that two specific genes are important.
Methodology
The study involved genotyping five genetic variants in a large dataset of Alzheimer's patients and controls, followed by meta-analysis.
Limitations
The associations for some variants did not survive adjustment for covariates, indicating potential dependency on other factors.
Participant Demographics
Caucasian subjects from the USA and Europe.
Statistical Information
P-Value
p = 5 × 10-4 for EPHA1; p = 0.049 for CD33
Confidence Interval
95% CI not specified
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website